HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Puig USA Accelerated Launches, New License Arrangement Planned

This article was originally published in The Rose Sheet

Executive Summary

Puig plans to boost the contribution of its U.S. beauty business to worldwide sales to 20% by accelerating launches under its core fragrance brands and adding a new licensing arrangement, according to Puig USA President and General Manger, North America Beauty Kathy Cullin. The U.S. currently represents about 12% of worldwide company revenues, she noted.

You may also be interested in...



Carolina Herrera Chic Ad Campaign To Include 10 Mil. Impressions

Spanish beauty firm Puig will support the launch of Carolina Herrera's Chic women's fragrance with its largest marketing effort in a decade, which will include 10 million ad impressions, USA President/General Manager of North America Kathy Cullin said

Carolina Herrera Chic Ad Campaign To Include 10 Mil. Impressions

Spanish beauty firm Puig will support the launch of Carolina Herrera's Chic women's fragrance with its largest marketing effort in a decade, which will include 10 million ad impressions, USA President/General Manager of North America Kathy Cullin said

Nina Ricci Premier Jour Adds Modernity To Fragrance Stable

The Nina Ricci fashion and beauty house is pursuing its "desire for renewal" with the introduction of Premier Jour women's scent. The French brand's first fragrance offering in 53 years, Premier Jour is slated to bow stateside in September.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel